Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 7,040 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of the stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $52.76, for a total value of $371,430.40. Following the completion of the sale, the chief executive officer directly owned 74,760 shares of the company’s stock, valued at approximately $3,944,337.60. The trade was a 8.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Bendheim also recently made the following trade(s):

• On Tuesday, April 28th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $55.91, for a total value of $393,606.40.
• On Wednesday, April 22nd, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.29, for a total value of $382,201.60.
• On Thursday, April 16th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.64, for a total value of $384,665.60.
• On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $59.08, for a total value of $415,923.20.
• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total value of $369,740.80.
• On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total value of $556,300.80.
• On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total value of $272,764.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total value of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total value of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total value of $361,644.80.

Phibro Animal Health Trading Up 1.3%

Shares of PAHC stock opened at $53.18 on Friday. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 0.81 and a beta of 0.69. The stock has a 50-day moving average of $53.86 and a 200-day moving average of $46.10. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14. Phibro Animal Health Corporation has a 1-year low of $18.33 and a 1-year high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The business had revenue of $373.91 million during the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, equities research analysts forecast that Phibro Animal Health Corporation will post 3.03 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th were paid a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, March 4th. This represents a $0.48 annualized dividend and a yield of 0.9%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 21.33%.

Key Headlines Impacting Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Phibro amended and expanded its revolving credit facility commitment on April 28, improving liquidity and financial flexibility—an item investors typically view as reducing refinancing risk and supporting growth/capital allocation. Phibro Animal Health Expands Revolving Credit Facility Commitment
• Neutral Sentiment: The company scheduled its third-quarter results release for May 6 and a conference call/webcast for May 7 — a near-term catalyst that could move the stock depending on results vs. expectations. Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results
• Neutral Sentiment: Recent analyst/market commentary has included PAHC in value and GARP stock lists and compared it to peers (e.g., Zacks piece vs. Insulet), which can attract attention from growth-at-a-reasonable-price investors but is not an immediate fundamental change. PAHC vs. PODD: Which Stock Is the Better Value Option?
• Negative Sentiment: CEO Jack Bendheim sold multiple blocks of PAHC shares late April (total reported ~21,120 shares across filings), reducing his ownership; such insider selling can be perceived negatively by the market. Management says the trades were executed under pre-arranged Rule 10b5-1 plans, which moderates the signal but does not eliminate investor concern. SEC Filing Phibro Animal Health’s (PAHC) CEO Sold 21,120 Shares for $1.2 Million

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Phibro Animal Health by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock valued at $57,519,000 after acquiring an additional 13,884 shares during the period. State Street Corp grew its stake in Phibro Animal Health by 5.4% in the fourth quarter. State Street Corp now owns 942,279 shares of the company’s stock valued at $35,204,000 after acquiring an additional 48,243 shares during the period. Millennium Management LLC grew its stake in Phibro Animal Health by 4,227.1% in the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after acquiring an additional 626,492 shares during the period. Geode Capital Management LLC grew its stake in Phibro Animal Health by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock valued at $21,265,000 after acquiring an additional 21,951 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Phibro Animal Health by 1.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock valued at $18,394,000 after acquiring an additional 6,826 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Wall Street Analysts Forecast Growth

PAHC has been the subject of several recent analyst reports. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Morgan Stanley set a $49.00 target price on Phibro Animal Health in a research note on Friday, February 6th. Finally, Citigroup initiated coverage on Phibro Animal Health in a research note on Wednesday, April 15th. They set a “neutral” rating and a $62.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $42.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.